Critical Review of Data in Follicular Lymphoma

Critical Review of Data in Follicular Lymphoma

Critical Review of Data in Follicular Lymphoma

Explore the many current and emerging therapeutic options for patients with R/R FL and hear about recent clinical trial data on EZH2 inhibition.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Loretta J. Nastoupil, MD
    Associate Professor, Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Contracted Research: BMS/Celgene, Epizyme, Genentech, Janssen, Novartis
    Consulting Fees: ADC, Bayer, BMS/Celgene, Epizyme, Genentech, Gilead, Janssen, MorphoSys

    Gilles Salles, MD
    Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees: AbbVie, BeiGene, BMS/Celgene, Debiopharm, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, Janssen, Incyte, Ipsen, Miltenyi, MorphoSys, Novartis, VelosBio
    Contracted Research: MorphoSys

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Compare the safety and efficacy of available and emerging therapies for the treatment of relapsing/refractory follicular lymphoma
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists and hematologist oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Epizyme.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free